Evidence map›Paper›PMID 33546225›Full record

ArticleMolecules (Basel, Switzerland)2021

Synthesis and Anti-Hepatocarcinoma Effect of Amino Acid Derivatives of Pyxinol and Ocotillol.

Ying Zhang, Hui Yu, Shuzheng Fu, Luying Tan, Junli Liu, Baisong Zhou, Le Li, Yunhe Liu, Caixia Wang, Pingya Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ying ZhangSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Hui YuSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Shuzheng FuSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Luying TanSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Junli LiuSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Baisong ZhouSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Le LiSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Yunhe LiuSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Caixia WangSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Pingya LiSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.
Jinping LiuSchool of Pharmaceutical Sciences, Jilin University, Fujin Road 1266, Changchun 130021, China.ORCID 0000-0003-4020-879X
Jilin University · CN

Funding

Jilin Province Development and Reform Commission 2020C038-3Jilin Scientific and Technological Development Program 20200301002RQJilin University 101832020CX315
6 · The paper itself

Abstract

Aiming at seeking an effective anti-hepatocarcinoma drug with low toxicity, a total of 24 amino acid derivatives (20 new along with 4 known derivatives) of two active ocotillol-type sapogenins (pyxinol and ocotillol) were synthesized. Both in vitro and in vivo anti-hepatocarcinoma effects of derivatives were evaluated. At first, the HepG2 human cancer cell was employed to evaluate the anti-cancer activity. Most of the derivatives showed obvious enhanced activity compared with pyxinol or ocotillol. Among them, compound

Indexed as

Antineoplastic AgentsAmino AcidsAnimalsCarcinoma, HepatocellularGinsenosidesHep G2 CellsHumansLiver NeoplasmsMiceStructure-Activity RelationshipXenograft Model Antitumor AssaysAmino AcidsAntineoplastic AgentsGinsenosidesocotillolamino acid derivativesanti-hepatocarcinomametabolomicsocotillolpyxinol

Identifiers

PMID33546225
PMCPMC7913291
OpenAlexW3126405884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.